Land: Canada
Språk: engelsk
Kilde: Health Canada
AMOXICILLIN (AMOXICILLIN TRIHYDRATE); CLAVULANIC ACID (CLAVULANATE POTASSIUM)
AURO PHARMA INC
J01CR02
AMOXICILLIN AND BETA-LACTAMASE INHIBITOR
875MG; 125MG
TABLET
AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875MG; CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125MG
ORAL
100
Prescription
AMINOPENICILLINS
Active ingredient group (AIG) number: 0234720005; AHFS:
APPROVED
2018-01-09
_AURO-AMOXICLAV PRODUCT MONOGRAPH _ Page 1 of 34 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-AMOXICLAV Amoxicillin and Clavulanate Potassium Tablets, USP Amoxicillin (as amoxicillin trihydrate) and Clavulanic acid (as clavulanate potassium) 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg COMBINATIONS OF PENICILLINS, INCLUDING BETA-LACTAMASE INHIBITORS ATC CODE: J01CR02 AURO PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada Date of Initial Authorization: April 03, 1984 Date of Revision: June 7, 2023 Submission Control Number: 271369 _AURO-AMOXICLAV PRODUCT MONOGRAPH _ Page 2 of 34 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Immune 06/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ..................................................................................................................... 4 1.1 Pediatrics ........................................................................................................................................... 4 1.2 Geriatrics ........................................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ............................................................................ 5 4.4 Administration ............................ Les hele dokumentet